^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Columvi (glofitamab-gxbm)

    i
    Other names: RG6026, RO7082859, CD20 TCB, RG 6026, RO-7082859, RO 7082859, anti-CD20 CD3 TCB, RG-6026
    Company:
    Biogen, Roche
    Drug class:
    CD20 inhibitor, CD3 agonist
    Related drugs:
    7d
    TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Brown University
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD4 (CD4 Molecule) • IRF4 (Interferon regulatory factor 4)
    |
    Gazyva (obinutuzumab) • Monjuvi (tafasitamab-cxix) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    11d
    Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with Glofitamab. (PubMed, Cancers (Basel))
    LAG3 rs870849 may be a prognostic response marker in R/R DLBCL treated with glofitamab.
    Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Columvi (glofitamab-gxbm)
    11d
    A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma (clinicaltrials.gov)
    P1, N=39, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    lenalidomide • Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)
    20d
    UPCC 48420: CAR-T Followed by Bispecific Antibodies (clinicaltrials.gov)
    P2, N=42, Recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Jun 2027 --> Dec 2028 | Trial primary completion date: Jun 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Gazyva (obinutuzumab) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm)
    20d
    Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    gemcitabine • Gazyva (obinutuzumab) • oxaliplatin • Columvi (glofitamab-gxbm)
    20d
    SKYGLO: An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=1130, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Dec 2027 --> Oct 2027
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    22d
    Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, Henan Cancer Hospital
    New trial • HEOR • Real-world evidence
    |
    Columvi (glofitamab-gxbm)
    22d
    BiCAR: Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy (clinicaltrials.gov)
    P2, N=67, Completed, The Lymphoma Academic Research Organisation | Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> May 2025
    Trial completion • Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)
    1m
    Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy (clinicaltrials.gov)
    P2, N=41, Not yet recruiting, Fondazione Italiana Linfomi - ETS
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Columvi (glofitamab-gxbm)
    1m
    A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=41, Recruiting, Jennifer Crombie, MD | Active, not recruiting --> Recruiting
    Enrollment open
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    1m
    Case report of two patients with refractory HIV-related B-cell lymphoma treated with the monoclonal antibody glofitamab for secondary central nervous system involvement. (PubMed, Front Oncol)
    Preliminary reports indicate that the monoclonal antibody glofitamab can penetrate the blood-brain barrier, inducing clinical responses in CNS DLBCL patients by activating T lymphocytes. This report presents preliminary clinical evidence on the use of glofitamab in HIV-positive patients with secondary CNS lymphoma.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Columvi (glofitamab-gxbm)
    1m
    Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, National Cancer Institute (NCI)
    New P1 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    cisplatin • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • vincristine • daunorubicin • Truxima (rituximab-abbs) • Columvi (glofitamab-gxbm) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)